News 09.07.2019 Schlieren (Zurich), Switzerland, July 9, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group (ASX: PGC), a leading provider of medical...
News 09.05.2019 Zurich-Schlieren, May 9, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, announced today its Interim Management Statement for the period ending March 31, 2019. “Our team is focused on delivering on our strategic priorities by advancing clinical candidates MP0250 and...
News 17.04.2019 Zurich-Schlieren, Switzerland, April 16, 2019. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, the shareholders of the company approved all motions proposed by the Board of Directors with a very large majority. At today’s...
News 15.04.2019 Schlieren (Zurich), Switzerland, April 12, 2019 – Kuros Biosciences successfully delivered on its targets in 2018, realizing first sales of MagnetOs and confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. Kuros raised gross proceeds of CHF 16.1 million from a capital increase to advance...
News 09.04.2019 Schlieren (Zurich), Switzerland, April 9, 2019 – Kuros Biosciences (SIX: KURN) today announced that it has entered into a convertible bond financing agreement with Nice & Green S.A. for up to a maximum of CHF 5 million. The facility is provided by Nice & Green, a private Swiss company which specializes...